Accutane (Isotretinoin) Side Effects: Potentially Permanent Adverse Events Explained

Which side effects can actually persist?

Isotretinoin is a retinoid approved only for severe recalcitrant nodular acne (inflammatory nodules 5 mm or larger) in non-pregnant patients 12 and older who have not responded to conventional therapy, including systemic antibiotics [1]. The older-format Accutane label states that most adverse reactions reported in clinical trials were reversible when therapy was discontinued, but that some persisted after cessation [2].

The labels name three effects as possibly lasting. The Accutane label lists decreased night vision which may persist, and alopecia which in some cases persisted [2]. The Absorica/Absorica LD label lists sexual dysfunction that may continue after discontinuation of treatment, including erectile dysfunction, decreased libido, decreased vaginal lubrication and vaginal dryness [1]. Corneal opacities, premature epiphyseal closure, skeletal hyperostosis, calcification of tendons and ligaments and decreases in bone mineral density also appear in the labels' reaction lists [1][2]. The label says some of these reactions were reported voluntarily from a population of uncertain size, so frequency cannot always be reliably estimated and a causal relationship cannot always be established [1].

Birth defects: what the boxed warning covers

The Absorica and Absorica LD label opens with a boxed warning, EMBRYO-FETAL TOXICITY — CONTRAINDICATED IN PREGNANCY, stating that there is an extremely high risk of life-threatening birth defects if pregnancy occurs while taking any amount of the drug, even for short periods, and that potentially any exposed fetus can be affected [1]. The label also states there are no accurate means of determining prenatally whether an exposed fetus has been affected [1].

The malformations documented after isotretinoin exposure include abnormalities of the face, eyes, ears, skull, central nervous system, cardiovascular system, and thymus and parathyroid glands; external abnormalities such as anotia, micropinna, small or absent external auditory canals, microphthalmia, facial dysmorphia and cleft palate; and internal abnormalities including cerebral and cerebellar malformations, hydrocephalus, microcephaly and cranial nerve deficit [1][2]. In some cases death has occurred as a result of the malformations, and IQ scores below 85 with or without other abnormalities have been reported in children exposed in utero [1]. An increased risk of spontaneous abortion and premature births has also been reported [1].

Because of the risk of embryo-fetal toxicity, isotretinoin is available only through the iPLEDGE REMS, a shared program that covers all FDA-approved isotretinoin products and requires prescribers, pharmacies and patients to be enrolled [1][3]. The label says patients must not donate blood during treatment and for 1 month after the last dose, because the blood might be given to a pregnant patient, and that breastfeeding is not recommended during treatment and for at least 8 days after the last dose [1].

FDA approved modifications to iPLEDGE on 2026-02-09, including prescriber-permitted home pregnancy tests during and after treatment; FDA's page lists 2026-11-15 as the planned implementation date after an earlier delay [3][4]. Pre-treatment pregnancy tests must still be completed in a medical setting [3].

Bone: growth plates, bone density and hyperostosis

The Absorica/Absorica LD label's Warnings and Precautions section groups musculoskeletal abnormalities (arthralgias, back pain, decreases in bone mineral density and premature epiphyseal closure), and the adverse-reaction list also includes skeletal hyperostosis and calcification of tendons and ligaments [1]. The label states that long-term use, even at low doses, has not been studied and is not recommended, and that the effect of long-term use on bone loss is unknown [1]. It also notes that the optimal interval before retreatment has not been defined for patients who have not completed skeletal growth [1].

Skeletal imaging data come from a setting different from acne treatment. In a 1984 study, eight patients aged 5 to 26 with disorders of keratinization (six with ichthyosis, one with Darier disease, one with palmoplantar keratoderma) took isotretinoin for 9 months to 1 year at an average dose of 2 mg/kg/day (range 1.0 to 2.9 mg/kg/day); after 1 year, six of the eight had small but unequivocal skeletal hyperostoses, and five had multiple hyperostoses [5]. For comparison, the Accutane label allows up to 2 mg/kg/day in adults whose disease is very severe with scarring or mainly on the trunk, as tolerated [2].

Eyes: night vision, cornea and meibomian glands

The label instructs that if visual symptoms occur, treatment should be discontinued and the patient referred for an ophthalmological exam [1]. Its reaction list includes corneal opacities, decreased night vision which may persist, cataracts, optic neuritis, photophobia and dry eyes [1][2].

A 2001 review of 1,741 spontaneous case reports and the world literature classified 38 ocular signs and symptoms by causality [6]. Rated certain were abnormal meibomian gland secretion, meibomian gland atrophy, blepharoconjunctivitis, corneal opacities, decreased dark adaptation, decreased tolerance to contact lenses, keratitis, photophobia and ocular sicca; rated probable or likely were decreased color vision (reversible) and permanent loss of dark adaptation; permanent keratoconjunctivitis sicca was rated a possible association [6]. Those categories reflect case-report causality assessment, not measured incidence.

A 2015 review of meibomian gland effects describes dry-eye symptoms with reduced secretory function of the glands, even when meibography shows normal-appearing meibomian gland structure and eyelid margin inflammation is minimal [7]. The same review states there is currently no definitive method to restore the structure and function of damaged meibomian glands, so treatment is mainly palliative [7].

Hair, skin and scarring

Alopecia appears in the adverse-reaction list with the note that in some cases it persisted, and hair abnormalities, peeling of palms and soles, and abnormal wound healing (delayed healing or exuberant granulation tissue with crusting) are also listed [2]. The label advises avoiding wax epilation and skin resurfacing procedures (dermabrasion or laser) during treatment and for at least 6 months afterward because of scarring [1][2].

Sexual function

The Absorica/Absorica LD label's adverse-reaction section lists sexual dysfunction that may continue after discontinuation of treatment, naming erectile dysfunction, decreased libido, decreased vaginal lubrication and vaginal dryness [1]. Abnormal menses is listed separately [1].

Psychiatric effects: a warning, not a boxed warning

The boxed warning on isotretinoin is embryo-fetal toxicity only [1]. Psychiatric disorders appear under Warnings and Precautions: the label states the drug may cause depression, psychosis and, rarely, suicidal ideation, suicide attempts, suicide, and aggressive or violent behaviors [1]. The label directs prescribers to ask about psychiatric history before treatment and to assess for depression, mood disturbance, psychosis or aggression at each visit, and instructs patients or caregivers to stop the drug and promptly contact their health care provider if those symptoms develop, adding that discontinuation may be insufficient and further evaluation may be needed [1]. Neither label states that depression is permanent; in patients who reported depression, some said it subsided when the drug was discontinued and recurred when it was restarted [1][2].

A small imaging study measured brain metabolism with FDG-PET before and after 4 months of treatment in 13 adults taking isotretinoin and 15 taking an antibiotic; orbitofrontal cortex metabolism fell 21% with isotretinoin versus a 2% change with the antibiotic, but there were no differences in the severity of depressive symptoms between the two groups before or after treatment [8].

Inflammatory bowel disease

The label lists inflammatory bowel disease as a warning and directs that treatment be discontinued for abdominal pain, rectal bleeding or severe diarrhea; the adverse-reaction list includes inflammatory bowel disease, colitis and ileitis [1].

A 2010 case-control study using a large insurance claims database compared 8,189 people with incident IBD (3,664 Crohn disease, 4,428 ulcerative colitis, 97 unspecified) with 21,832 matched controls [9]. Sixty subjects had isotretinoin exposure. Ulcerative colitis was strongly associated with prior exposure (odds ratio 4.36, 95% CI 1.97 to 9.66), while Crohn disease was not (odds ratio 0.68, 95% CI 0.28 to 1.68); risk of ulcerative colitis was highest in those exposed for more than 2 months (odds ratio 5.63, 95% CI 2.10 to 15.03), and each 20 mg increase in dose was associated with higher risk (odds ratio 1.50, 95% CI 1.08 to 2.09) [9]. The authors wrote that the absolute risk of developing ulcerative colitis after taking isotretinoin is likely quite small [9].

Liver, lipids and pancreas

The Absorica label calls for a fasting lipid profile and liver function tests in all patients before prescribing, and monitoring of liver function tests before and during treatment [1]. On the lipid side, the Accutane label reports triglyceride elevations above 800 mg/dL, marked triglyceride elevations in approximately 25% of patients in clinical trials, a high-density lipoprotein decrease in about 15%, and a cholesterol increase in about 7%, and states that in clinical trials these effects on triglycerides, HDL and cholesterol were reversible upon cessation [2]. Acute pancreatitis has been reported in patients with either elevated or normal serum triglycerides, and in rare instances fatal hemorrhagic pancreatitis has been reported; the label says treatment should be stopped if hypertriglyceridemia cannot be controlled or if pancreatitis symptoms occur [2].

Course length

The Accutane label's dose is 0.5 to 1 mg/kg/day in two divided doses with food for 15 to 20 weeks, and it does not state a cumulative mg/kg target [2]. The Absorica label says a second course is not recommended before a 2-month waiting period, because acne may continue to improve after a 15 to 20-week course [1].